Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Colorectal Neoplasms 2Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Leiomyosarcoma 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

Sorafenib 79pembrolizumab 37Bevacizumab 36Nivolumab 33lenvatinib 30atezolizumab 24durvalumab 17Oxaliplatin 12Ipilimumab 12regorafenib 9Capecitabine 9tremelimumab 8Injections 8Doxorubicin 8tislelizumab 7sintilimab 7Fluorouracil 7cabozantinib 6budigalimab 6brivanib 6Ramucirumab 6toripalimab 5Gemcitabine 5Everolimus 5Cyclophosphamide 5ADI PEG20 5fludarabine 4Sunitinib 4Leucovorin 4E-7386 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Hepatocellular × cixutumumab × Clear all
NCT00906373 2018-06-04

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

Eli Lilly and Company

Phase 2 Completed
47 enrolled 14 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡